Parabilis Medicines Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Selling, General & Admin	33.01	22.27	21.13
Research & Development	125.58	125.58	100.83
Operating Expenses	158.59	147.85	121.96
Operating Income	-171.54	-147.85	-121.96
Interest Expense	-1.23	-1.52	-1.49
Interest & Investment Income	7.7	3.39	6.41
Other Non Operating Income (Expenses)	-5.46	0.1	-0.88
Pretax Income	-170.53	-145.89	-117.91
Net Income	-170.53	-145.89	-117.91
Preferred Dividends & Other Adjustments	61.14	41.04	43.57
Net Income to Common	-231.67	-186.93	-161.48
Net Income Growth	-	-	-
Shares Outstanding (Basic)	10	3	3
Shares Outstanding (Diluted)	10	3	3
Shares Change	-	4.59%	-
EPS (Basic)	-23.45	-60.04	-54.25
EPS (Diluted)	-23.45	-60.04	-54.25
EPS Growth	-	-	-
Free Cash Flow	-112.49	-124.02	-104.49
Free Cash Flow Per Share	-11.38	-39.83	-35.10
EBITDA	-169.11	-145.35	-119.85
D&A For EBITDA	2.43	2.5	2.11
EBIT	-171.54	-147.85	-121.96

SEC Filings: 10-K · 10-Q